Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity
Sign Up to like & getrecommendations! Published in 2022 at "Research in Pharmaceutical Sciences"
DOI: 10.4103/1735-5362.350243
Abstract: Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in… read more here.
Keywords: rovalpituzumab antibody; design two; analysis; structure ... See more keywords